Biotec BetaGlucans gets funding for next-gen bioactive wound healing products

Norwegian company has received NOK 8 million to develop an industry-first bioactive gel-forming fibre dressing containing soluble beta-glucan

Biotec BetaGlucans has been awarded up to NOK 8 million (US$945k) in a grant by the Research Council of Norway. A subsidiary of Biotec Pharmacon, the Tromso-based company will use the funding for a project titled “Bioactive wound healing dressing with beta-glucan for treatment of hard-to-heal wounds”. The project is to be supported over four years.

The grant has been awarded from the user-driven Research-based Innovation Programme (BIA). The focus of the research will be to develop first of its kind bioactive gel-forming fibre dressings. These dressings will contain soluble beta-glucan (SBG) for the treatment of hard-to-heal wounds by re-activating the healing process.

The project aims to develop new and cost-effective wound healing devices for the treatment of large hard-to-heal wounds, exuding wounds (burns and ulcers), donor-site wounds, and wounds on mucosal surfaces.

CEO Christian Jørgensen commented: “We are pleased to have been awarded this grant, which serves as a great testament to the hard work being done at Biotec BetaGlucans. It will help us develop a broader set of treatments for the many people suffering from different types of hard-to-heal wounds.”

Established in 2006, the BIA programme is one of the largest programmes at the Research Council and is a key partner for Norwegian trade and industry. This broad-based programme supports high-quality R&D projects with good business and socio-economic potential.

The award is subject to successful contract negotiations between the parties.

Companies